Invion

Invion Cash & Equivalents

The Cash & Short-Term Investments of Invion (IVX.AX) as of Oct 29, 2026 is 592,311.00 AUD. In the previous year, Cash & Short-Term Investments was 850,373.00 AUD — a change of -30.35% (lower).

Cash & Equivalents

592,311.00AUD

YoY

-30.35%

Last updated:

Cash & Short-Term Investments of Invion is 2026 592,311.00 AUD. Cash & Short-Term Investments of Invion was 2025 850,373.00 AUD. It decreases by -30.35% lower compared to the previous year.

The Invion Cash & Equivalents history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash & Equivalents
Date
Cash & Equivalents
Jan 1, 2019
771,313.00 AUD
Jan 1, 2020
618,843.00 AUD
Jan 1, 2021
1.04 M AUD
Jan 1, 2022
8.47 M AUD
Jan 1, 2023
4.08 M AUD
Jan 1, 2024
783,526.00 AUD
Jan 1, 2025
850,373.00 AUD
Jan 1, 2026
592,311.00 AUD
The Invion Cash & Equivalents history
YEARCash & EquivalentsYoY
592,311.00AUD-30.35%
850,373.00AUD+8.53%
783,526.00AUD-80.82%
4.08 MAUD-51.79%
8.47 MAUD+717.25%
1.04 MAUD+67.54%
618,843.00AUD-19.77%
771,313.00AUD-73.32%
2.89 MAUD+215.14%
917,486.00AUD+109.76%
437,399.00AUD-80.85%
2.28 MAUD-42.20%
3.95 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

Cash & Short-Term Investments of Invion is 592,311.00 AUD in 2026.

Cash & Short-Term Investments of Invion changed from 850,373.00 AUD to 592,311.00 AUD, representing a -30.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Cash & Short-Term Investments Invion since 2006 – with annual values, charts, and detailed analysis.

Cash and equivalents represent the most liquid assets on the balance sheet, available for immediate use or short-term obligations.

Cash & Short-Term Investments's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Cash & Short-Term Investments's Invion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Invion

All Key Metrics — Invion